Switching from originator infliximab to a biosimilar, CT-P13 (Inflectra), does not result in any change in efficacy or safety in IBD patients up to 18 months, new results from the NOR-SWITCH extension trial show. Presenting findings from a six-month open label follow up of the 52-week NOR-SWITCH trial, researchers from Norways told DDW 2018 there ...
Biosimilar switching safe for infliximab in NOR-SWITCH Extension trial
By Michael Woodhead
13 Jun 2018